one18

Stories

Natco Pharma Boosts eGenesis Investment to $16.7M for Gene-Edited Organ Research
C
CNBC TV18•28-09-2026, 16:33
Natco Pharma Boosts eGenesis Investment to $16.7M for Gene-Edited Organ Research
  • •Natco Pharma increased its investment in US biotech eGenesis Inc. to $16.7 million from $14 million, as disclosed on September 28.
  • •The investment will be made through Natco Pharma's wholly owned subsidiaries, Natco Pharma (Canada) Inc. and Natco Pharma USA LLC, via convertible promissory notes with an 8% annual interest rate.
  • •Following this update, Natco Pharma's total investment in eGenesis will reach $24.7 million, including an $8 million investment made earlier in 2024.
  • •eGenesis develops gene-editing technology to modify pig organs for human transplantation, aiming to address organ shortages and reduce rejection risks.
  • •eGenesis gained recognition in March 2024 for performing the world's first pig-kidney transplant in a living patient, authorized by the US FDA.
Read Full Article on CNBC TV18 in English

Key Questions Answered

Natco Pharma increased its proposed investment in eGenesis Inc. to $16.7 million, bringing its cumulative investment in the US biotech firm to $24.7 million including a previous $8 million investment made in 2024.

The investment will be executed via Natco Pharma's wholly owned subsidiaries, specifically Natco Pharma (Canada) Inc. providing $13.7 million and Natco Pharma USA LLC contributing $3 million, through convertible promissory notes with an 8% annual compounded interest rate.

eGenesis develops genome-engineering and multiplex gene-editing technology to modify pig organs for transplantation into humans, addressing critical organ shortages while reducing rejection risks and viral transmission across species.

Similar Stories

Natco Pharma has raised its proposed eGenesis investment to $16.7 million, taking its total investment in the US biotech firm to $24.7 million.

Natco Pharma Boosts eGenesis Investment to $16.7 Million, Total Bet Reaches $24.7 Million

M
Moneycontrol
Gland Pharma | Jefferies has a "buy" rating and a target price of 3,350 per share on the stock. It said the company's wholly-owned subsidiary Cenexi has finally turned around, achieved sustainable EBITDA breakeven and has a healthy demand outlook to deliver double-digit constant currency growth over the next three years. It said the US geography is firmly back on a growth path, supported by 3-4 differentiated product launches over the past six months. Jefferies expects the ramp-up of newly-launched products and an expanding complex product portfolio to drive a high-teens CAGR in the region. It said the management's guidance of 20% total sales growth over the next four years is significantly higher than consensus estimates of mid-teens growth and leaves room for consistent earnings upgrade. It values the stock at 32x September 2028 EPS estimates and it assigns high multiple on significantly higher sales/EBITDA growth and stronger execution in recent few quarters.

Gland Pharma Invests $21 Million in US Drugmaker, Acquires 60% Stake in Novelstar Pharma

C
CNBC TV18
Natco Pharma Launches Carboplatin Injection in US Market, Shares Rise 2%

Natco Pharma Launches Carboplatin Injection in US Market, Shares Rise 2%

C
CNBC TV18
Representational image (Image: News18)

RBI Forex Swap Facility Inflows Soar to $143.6 Billion

N
News18
Meesho Shares Soar 11% as UBS Raises Target Price to ₹260

Meesho Shares Soar 11% as UBS Raises Target Price to ₹260

C
CNBC TV18
OpenAI is reportedly seeking at least $30 billion at a $1.4 trillion valuation after Sam Altman pushed back the ChatGPT maker’s IPO plans.

OpenAI Eyes $1.4 Trillion Valuation in $30 Billion Funding Round After IPO Delay

M
Moneycontrol